Algernon Pharmaceuticals Inc.  a clinical stage pharmaceutical development company, is pleased to announce that it has recently received approximately $600,000 CDN in the form of a refundable tax credit from its clinical research work in Australia. The expenses being refunded are from the Company’s Ifenprodil IPF and chronic cough Phase 2 clinical study program. Since the Phase 2 trial is still in progress, the …

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has recently received approximately $600,000 CDN in the form of a refundable tax credit from its clinical research work in Australia. The expenses being refunded are from the Company’s Ifenprodil IPF and chronic cough Phase 2 clinical study program. Since the Phase 2 trial is still in progress, the company plans to submit additional eligible expenses for reimbursement from the tax refund program, in due course.

“Algernon’s unique business model of drug repurposing includes conducting as much clinical research as possible in Australia in order to take advantage of the Australian Government’s 41% refundable tax credit program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This refund, while expected, is an important part of our capital efficient R&D plan to drive value for our shareholders by keeping our research costs to an absolute minimum as we conduct early clinical investigations into the efficacy of our re-purposed compound targets.”

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release .

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year.

NP-120 (Ifenprodil) Idiopathic Pulmonary Fibrosis (IPF) & Chronic Cough Clinical Research Program

Keep reading... Show less

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year.

NP-120 (Ifenprodil) Idiopathic Pulmonary Fibrosis (IPF) & Chronic Cough Clinical Research Program

Keep reading... Show less

Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75% of its enrollment target, which is 113 patients, for its multinational Phase 2b3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.

The multinational human trial is being conducted in the U.S., Australia, the Philippines and Romania.

Keep reading... Show less

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year.

NP-120 (Ifenprodil) Idiopathic Pulmonary Fibrosis (IPF) & Chronic Cough Clinical Research Program

Keep reading... Show less

Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75% of its enrollment target, which is 113 patients, for its multinational Phase 2b3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.

The multinational human trial is being conducted in the U.S., Australia, the Philippines and Romania.

Keep reading... Show less

Lake Resources NL Quarterly Activities Report

Sydney, Australia (ABN Newswire) – Lake Resources NL (ASX:LKE) (FRA:LK1) (OTCMKTS:LLKKF) is a lithium developer utilising clean, direct extraction technology for the development of high purity lithium products with significant ESG benefits from its flagship Kachi Project (4.4mt LCE resource), and three other lithium brine projects in Argentina. No mining is involved in the brine processing.

Lake owns over 220,000 hectares (0.5 million acres) of leases in a prime location within the Lithium Triangle, alongside all 5 major lithium producers.

A key difference in Lake’s development plan to lithium production is to use an efficient direct lithium extraction method (DLE) from our technology partner, Lilac Solutions Inc. This enables Lake Resources to be a cost competitive supplier of high-purity lithium carbonate with a low carbon (CO2) footprint, low water use and low land use – strong Environmental, Social, Governance (ESG) benefits.

Keep reading... Show less

How to Access Medical Cannabis in Australia

Recreational cannabis remains out of reach in Australia, but the country legalised medical cannabis in 2016, opening up access to the cannabis market for both Australians and investors alike.

Cannabis in Australia is used to treat a myriad of conditions, from epilepsy to neuropathic pain, but federal legislation has a strict hold on the distribution of cannabis in the country.

Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval. However, there are signs that the limits to access are slowly lessening, including the approval of over-the-counter cannabidiol (CBD) products and new breakthroughs in government-sponsored medical cannabis research.

Keep reading... Show less

OceanaGold Reports Second Quarter 2021 Financial Results

/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES AND NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES./

(All financial figures in US Dollars unless otherwise stated)

Keep reading... Show less

Arcadia Minerals' Quarterly Activities Report JUNE QUARTER 2021

Arcadia Minerals Ltd (ASX:AM7) (Arcadia, AM7 or the Company) is pleased to present the Company's first quarterly activities report since listing on the ASX on the 25 June 2021.

Keep reading... Show less

Galan Lithium's Quarterly Activities Report JUNE 2021

The Board of Galan Lithium Limited ("Galan" or "the Company") is pleased to provide this Quarterly Activities Report for the quarter ended 30 June 2021 to the date of this report. The main focus for the quarter was the commencement of foundation feasibility works and the completion of proof-of-concept laboratory testing for its low carbon footprint brine evaporation process at its flagship Hombre Muerto West Project located in the South American Lithium Triangle in Catamarca, Argentina.

Keep reading... Show less

Comet Resources' Quarterly Activities Report – June 2021

Comet Resources Limited (Comet or the Company) (ASX:CRL), is pleased provide the Quarterly Activities Report and Appendix 5B for the quarter ending 30 June 2021 (the Quarter). The Company proactively progressed various exploration programs across its projects and successfully completed the acquisition of a portfolio of copper-gold and base metals assets in Australia's Northern Territory. Post Quarter end, the Company provided an update regarding the status of ongoing metallurgical test work on graphite from its Springdale Graphite Project located in Western Australia.

Keep reading... Show less

Top News

Related News